[Skip to content]

European Parkinson's Disease Association
Search our Site



Medication research papers

  • Neuroscience Letters L-DOPA treatment in MPTP-mouse model of Parkinson's disease potentiates homocysteine accumulation in substantia nigra.Authors found a significant elevation of Hcy level in nigrostriatum in naïve as well as parkinsonian mice as a result of chronic L-DOPA treatment. Interestingly, L-DOPA treatment significantly elevates Hcy level in nigra but not in striatum of parkinsonian mice, when compared with L-DOPA naïve group. However, there was no significant decrease in the number of dopaminergic neurons in SN region in the parkinsonian mice given L-DOPA treatment. 01 August 2016
  • The Journal of Clinical Pharmacology Dose-Response Analysis of the Effect of Carbidopa-Levodopa Extended Release Capsules (IPX066) in Levodopa-Naïve Parkinson'sNatural disease progression in early Parkinson's disease as measured by UPDRS was 11.6 units/year and faster in patients with more severe disease (Hoehn-Yahr stage 3). Maximum placebo/non-levodopa response was 23.0% of baseline UPDRS. Maximum levodopa effect from IPX066 was 76.7% of baseline UPDRS, and the ED50 was 450 mg levodopa. 01 August 2016
  • Brain Volume 139 Issue 4 Atomoxetine restores the response inhibition network in Parkinson's diseaseStudy results suggest that (i) atomoxetine increases sensitivity of the inferior frontal gyrus to afferent inputs from the pre-supplementary motor cortex; (ii) atomoxetine can enhance downstream modulation of frontal-subcortical connections for response inhibition; and (iii) the behavioural consequences of treatment are dependent on fronto-striatal structural connections. 01 August 2016
  • European Journal of Neurology A European multicentre survey of impulse control behaviours in Parkinson's treated with short- and long-actingStudy data suggest a relatively low rate of ICDs with long-acting or transdermal DAs, however these preliminary observational data need to be confirmed with prospective studies controlling for possible confounding factors. 01 August 2016
  • Human Gene Therapy Long-Term Safety of Patients with Parkinson's Disease Receiving rAAV2-Neurturin (CERE-120) Gene TransferThese findings provide evidence for the long-term safety of neurturin when delivered to the putamen or the putamen-plus-substantia nigra via stereotactic surgery and rAAV2 gene transfer. They therefore supplement the safety results reported in four prior publications from the same subjects, significantly extending the safety data for gene therapy and neurotrophic factor expression targeting the brain and adding to growing evidence that rAAV vector-mediated gene therapy to the CNS can be administered safely. 18 July 2016
  • Movement Disorders Volume 31 Issue 7 Mavoglurant in Parkinson's Patients With l-Dopa-Induced Dyskinesias: Two Randomized Phase 2 StudiesConclusions: Both studies failed to meet the primary objective of demonstrating improvement of dyskinesia with mavoglurant treatment. 15 July 2016
  • npj Parkinson's Disease Effect of levodopa-carbidopa intestinal gel on resting tremors in patients with advanced Parkinson's diseaseOut of 354 enrolled patients, 286 had baseline and post-PEG-J assessments of resting tremors and were included in this analysis. At baseline the majority of patients (69%) had no resting tremors, whereas 13% had mild resting tremors, and 18% had significant resting tremors. A complete resolution in resting tremors after 12 months of LCIG treatment was reported for 78% and 70% of patients with mild and significant baseline resting tremors, respectively. Improvements in motor complications and quality of lif 14 July 2016
  • PlosONE Bee Venom for the Treatment of Parkinson Disease A Randomized Controlled Clinical TrialThis study did not evidence any clear symptomatic or disease-modifying effects of monthly bee venom injections over an 11 month period compared to placebo using a standard bee venom allergy desensitization protocol in Parkinson disease patients. However, bee venom administration appeared safe in non-allergic subjects. Thus, authors suggest that higher administration frequency and possibly higher individual doses of bee venom may reveal its potency in treating Parkinson disease. 12 July 2016
  • Journal of Parkinson's Disease Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodiesThis small proof-of-concept study lacks a placebo group and participants were not homogenous, resulting in baseline differences between and within groups. This limits the interpretations of the biomarker and clinical data, and any conclusions should be drawn cautiously. Nonetheless, the collective observations suggest that it is warranted to evaluate the safety and efficacy of Nilotinib in larger randomized, double-blind, placebo-controlled trials. 11 July 2016
  • Planta Medica Medicinal Plants and Natural Products as Potential Sources for Antiparkinson DrugsIn this review, authors have compiled data on the principal medicinal plants and natural products as potential antiparkinsonian agents. They act by different mechanisms, such as the inhibition of α-synuclein condensation, reduction of oxidative stress and neuro-inflammation, increase of dopaminergic neurons survival, or the blockade of the A2 A receptor. 01 July 2016
Page: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [+11]